Athira Pharma Inc. (ATHA): Price and Financial Metrics


Athira Pharma Inc. (ATHA): $9.21

0.36 (+4.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATHA Stock Price Chart Interactive Chart >

Price chart for ATHA

ATHA Price/Volume Stats

Current price $9.21 52-week high $23.64
Prev. close $8.85 52-week low $7.56
Day low $8.77 Volume 378,800
Day high $9.73 Avg. volume 292,153
50-day MA $10.79 Dividend yield N/A
200-day MA $11.13 Market Cap 346.63M

Athira Pharma Inc. (ATHA) Company Bio


Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.


ATHA Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHA Latest Social Stream


Loading social stream, please wait...

View Full ATHA Social Stream

Latest ATHA News From Around the Web

Below are the latest news stories about Athira Pharma Inc that investors may wish to consider to help them evaluate ATHA as an investment opportunity.

Athira Pharma's Alzheimer's therapy ATH-1017 shows promise in phase 1 study

Athira Pharma (NASDAQ:ATHA) reported phase 1 trial of fosgonimeton (ATH-1017) in healthy volunteers and patients with Alzheimer’s disease. The data was published in The Journal of Alzheimer's Disease. The study included 48 healthy young male volunteers in a single ascending dose cohort; 29 healthy elderly volunteers in a multiple ascending dose cohort;...

Seeking Alpha | February 22, 2022

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer''s Disease

Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer''s disease patients Fosgonimeton was well-tolerated across all dose levels and showed dose-proportional pharmacokinetics and encouraging pharmacodynamic activity Announces fosgonimeton as World Health Organization''s recommended international nonproprietary name for ATH-1017 BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer''s D...

Benzinga | February 22, 2022

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models First presentation of preclinical data from ATH-1020 candidate for neuropsychiatric conditions BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that preclinical data for the active

Yahoo | February 22, 2022

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer’s disease patients Fosgonimeton was well-tolerated across all dose levels and showed dose-proportional pharmacokinetics and encouraging pharmacodynamic activity Announces fosgonimeton as World Health Organization’s recommended international nonproprietary name for ATH-1017 BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDA

Yahoo | February 22, 2022

Laird Norton Trust Company, Llc Buys iShares National Muni Bond ETF, iShares Core S&P 500 ...

Investment company Laird Norton Trust Company, Llc (Current Portfolio) buys iShares National Muni Bond ETF, iShares Core S&P 500 ETF, Airbnb Inc, ACV Auctions Inc, Athira Pharma Inc, sells MSCI USA ESG Select ETF, Vanguard S&P 500 ETF, iShares S&P 500 Growth ETF, Vanguard Growth ETF, FlexShares Global Quality FlexShares Global Qualit during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Laird Norton Trust Company, Llc.

Yahoo | February 7, 2022

Read More 'ATHA' Stories Here

ATHA Price Returns

1-mo -11.70%
3-mo -0.97%
6-mo -32.18%
1-year -53.81%
3-year N/A
5-year N/A
YTD -29.32%
2021 -61.96%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4538 seconds.